TY - JOUR
T1 - Seizures in patients with multiple sclerosis
T2 - Epidemiology, pathophysiology and management
AU - Kelley, Brendan J.
AU - Rodriguez, Moses
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health (R01 NS 24180, R01 NS 32129) and the National Multiple Sclerosis Society (RG 317 2-B-8, CA 1011 A8-3). The authors have no conflicts of interest that are directly relevant to the content of this review.
PY - 2009
Y1 - 2009
N2 - Seizures have been recognized to occur in multiple sclerosis (MS) since early descriptions of the disease. Various studies have attempted to determine the incidence and prevalence of seizures in MS; although they differ in the reported prevalence, seizures do appear to be more common in MS cohorts than in the general population.The pathological underpinning of seizures in MS remains indeterminate. Cortical and subcortical demyelination and inflammation may explain the increased frequency of seizures in MS, although this hypothetical correlation remains to be proven.Management of seizures in MS is similar to the management of seizures in other patients. Consideration of the underlying neurological deficits related to MS may be necessary, and dosages of antiepileptic drugs should be adjusted if increased sensitivity to the adverse effects of these agents or interaction with other centrally acting medications is suspected. The prognosis of epilepsy in patients with MS remains uncertain, with some studies suggesting a more favourable prognosis than others.
AB - Seizures have been recognized to occur in multiple sclerosis (MS) since early descriptions of the disease. Various studies have attempted to determine the incidence and prevalence of seizures in MS; although they differ in the reported prevalence, seizures do appear to be more common in MS cohorts than in the general population.The pathological underpinning of seizures in MS remains indeterminate. Cortical and subcortical demyelination and inflammation may explain the increased frequency of seizures in MS, although this hypothetical correlation remains to be proven.Management of seizures in MS is similar to the management of seizures in other patients. Consideration of the underlying neurological deficits related to MS may be necessary, and dosages of antiepileptic drugs should be adjusted if increased sensitivity to the adverse effects of these agents or interaction with other centrally acting medications is suspected. The prognosis of epilepsy in patients with MS remains uncertain, with some studies suggesting a more favourable prognosis than others.
UR - http://www.scopus.com/inward/record.url?scp=70349108297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349108297&partnerID=8YFLogxK
U2 - 10.2165/11310900-000000000-00000
DO - 10.2165/11310900-000000000-00000
M3 - Review article
C2 - 19739692
AN - SCOPUS:70349108297
SN - 1172-7047
VL - 23
SP - 805
EP - 815
JO - CNS Drugs
JF - CNS Drugs
IS - 10
ER -